Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001714899-25-000087
Filing Date
2025-04-17
Accepted
2025-04-17 16:05:24
Documents
26
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A dnli-20250417.htm   iXBRL DEF 14A 1129774
6 dnli-20250417_g1.jpg GRAPHIC 26538
7 dnli-20250417_g10.jpg GRAPHIC 204710
8 dnli-20250417_g2.jpg GRAPHIC 12023
9 dnli-20250417_g3.jpg GRAPHIC 16783
10 dnli-20250417_g4.jpg GRAPHIC 15697
11 dnli-20250417_g5.jpg GRAPHIC 19971
12 dnli-20250417_g6.jpg GRAPHIC 295114
13 dnli-20250417_g7.jpg GRAPHIC 120904
14 dnli-20250417_g8.jpg GRAPHIC 113363
15 dnli-20250417_g9.jpg GRAPHIC 469629
  Complete submission text file 0001714899-25-000087.txt   5009327

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20250417.xsd EX-101.SCH 4624
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20250417_def.xml EX-101.DEF 2983
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20250417_lab.xml EX-101.LAB 8664
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20250417_pre.xml EX-101.PRE 5967
28 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20250417_htm.xml XML 220266
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38311 | Film No.: 25847278
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)